Dublin, Aug. 30, 2016 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of the "Frontier Pharma: Rheumatoid Arthritis - Cytokine Mediators and Kinase Inhibitors Dominate First-in-Class Product Innovation" report to their offering.

Unmet needs in rheumatoid arthritis treatment could be addressed by first-in-class pipeline.

The rheumatoid arthritis market is highly lucrative and significant advances in the understanding of the disease have greatly improved treatment options for a large number of patients over the past two decades. However, serious unmet needs remain, and there are still many opportunities for future drug developments, particularly for first-in-class innovation, according to the publisher.

This latest report states that rheumatoid arthritis remains an incurable condition with no therapeutics that directly act to restore bone content and reduce cartilage degradation. Safety, often concerning elevated infection as a result of immunosuppression, remains a concern, while many patients respond inadequately or eventually develop resistance to first- and second-line therapies. In addition, biologics require either intravenous or subcutaneous administration, which is often inconvenient and painful for patients.

The current disease pipeline is relatively large, containing 454 products. While the proportion of first-in-class products in the pipeline is marginally lower than the industry average, it contains many first-in-class targets that have the potential to lead to therapeutic advances. In particular, there is a higher proportion and diversity of first-in-class molecular targets in the early development stages than in the clinical trial development stages.

This is an encouraging trend, revealing sustained research and development in rheumatoid arthritis. Nonetheless, limited first-in-class innovation at the later development stages suggests that the therapeutic landscape will continue to be dominated by currently marketed products in the near future.

This report also states that in terms of types of first-in-class products in the pipeline, cytokine and cytokine receptors, as well as protein kinases, largely dominate. Most first-in-class products targeting cytokines and their receptors are biologic therapies, and target a range of mediators that underlie inflammatory and adaptive immune responses in rheumatoid arthritis.

Key Topics Covered:

1 Tables & Figures

2 Executive Summary
2.1 A Crowded, Competitive Market, with Significant Unmet Needs Remaining
2.2 Early-Stage Pipeline Offers Greatest Promise for First-in-Class Innovation
2.3 Cytokine and Cytokine Receptors, as well as Protein Kinases, Largely Dominate First-in-Class Pipeline Products

3 The Case for Innovation
3.1 Growing Opportunities for Biologic Products
3.2 Diversification of Molecular Targets
3.3 Innovative First-in-Class Development Remains Attractive
3.4 Regulatory and Reimbursement Policy Shifts Favor First-in-Class Product Innovation
3.5 Sustained Innovation
3.6 Report Guidance

4 Clinical and Commercial Landscape
4.1 Disease Overview
4.2 Disease Symptoms
4.3 Epidemiology
4.4 Etiology
4.5 Pathophysiology
4.6 Co-morbidities and Complications
4.7 Diagnosis
4.8 Disease Progression
4.9 Treatment Options and Treatment Algorithm
4.10 Overview of Marketed Products in Rheumatoid Arthritis

5 Assessment of Pipeline Product Innovation
5.1 Rheumatoid Arthritis Pipeline by Stage of Development, Molecule Type and Molecular Target
5.2 Comparative Distribution of Programs between the Rheumatoid Arthritis Market and Pipeline by Therapeutic Target Family
5.3 First-in-Class Programs Targeting Novel Molecular Targets

6 Signaling Network, Disease Causation and Innovation Alignment
6.1 Complexity of Signaling Networks in Rheumatoid Arthritis
6.2 Signaling Pathways, Disease-Causing Mutations and First-in-Class Molecular Target Integration
6.3 First-in-Class Matrix Assessment

7 First-in-Class Target Evaluation
7.1 Pipeline Programs Targeting Tumor Necrosis Factor Receptor Superfamily Member 5 (CD40)
7.2 Pipeline Programs Targeting Non-Receptor Tyrosine-Protein Kinase TYK2 (TYK2)
7.3 Pipeline Programs Targeting IL-10 and IL-18
7.4 Pipeline Programs Targeting 72 kDa Type IV Collagenase (MMP2)
7.5 Pipeline Programs Targeting P2X Purinoceptor 7 (P2RX7)
7.6 Pipeline Programs Targeting Protein Kinase C Theta Type (PRKCQ)
7.7 Pipeline Programs Targeting C-C Motif Chemokine 4 (CCL4) and C-C Motif Chemokine 5 (CCL5)
7.8 Pipeline Programs Targeting C-X-C Motif Chemokine 10 (CXCL10) and C-X-C Motif Chemokine 13 (CXCL13)

8 Strategic Consolidations
8.1 Industry-Wide First-in-Class Deals
8.2 Licensing Deals
8.3 Co-development Deals
8.4 First-in-Class Programs Not Involved in Licensing or Co-development Deals

9 Appendix

For more information about this report visit http://www.researchandmarkets.com/research/gcnm8r/frontier_pharma

Related Topics: Pharmaceuticals, Musculoskeletal Disorders Drugs

CONTACT: Research and Markets
Laura Wood, Senior Manager

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716